CD274 and neoplasm: The co-primary endpoints were OS compared between durvalumab plus tremelimumab and chemotherapy in the ITT population and between durvalumab monotherapy and chemotherapy in PD-L1-positive patients (PD-L1 expression defined as ≥25% of tumor cells or immune cells) (see Table 1 for PD-L1 positivity).